A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphines

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 3, 2013, Pages 708-717

  DeWire, Scott M ^a   Yamashita, Dennis S ^a   Rominger, David H ^a   Liu, Guodong ^a   Cowan, Conrad L ^a   Graczyk, Thomas M ^a   Chen, Xiao Tao ^a   Pitis, Philip M ^a   Gotchev, Dimitar ^a   Yuan, Catherine ^a   Koblish, Michael ^a   Lark, Michael W ^a   Violin, Jonathan D ^a  

^a TREVENA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[[(3 METHOXYTHIOPEN 2 YL)METHYL][[2 [9 (PYRIDIN 2 YL) 6 OXASPIRO[4.5]DECAN 9 YL]ETHYL]]AMINE]; BETA ARRESTIN; G PROTEIN COUPLED RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALOXONE; TRV 130; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PAIN; PRIORITY JOURNAL; RAT; RESPIRATORY FAILURE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANALGESICS; ANIMALS; ARRESTINS; CELL LINE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; GTP-BINDING PROTEINS; HEK293 CELLS; HUMANS; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, OPIOID, MU; RESPIRATORY SYSTEM; RESPIRATORY TRACT DISEASES; SIGNAL TRANSDUCTION;

EID: 84874406899     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.201616     Document Type: Article

References (56)

1. Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, Peterson S, Yadav PN, Huang XP, and Feng B, et al. (2011) Discovery of b-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci USA 108:18488-18493.
2. Altier C and Zamponi GW (2004) Targeting Ca21 channels to treat pain: T-type versus N-type. Trends Pharmacol Sci 25:465-470.
3. Anastassopoulos KP, Chow W, Ackerman SJ, Tapia C, Benson C, and Kim MS (2011) Oxycodone-related side effects: Impact on degree of bother, adherence, pain relief, satisfaction, and quality of life. J Opioid Manag 7:203-215.
4. Audet N, Charfi I, Mnie-Filali O, Amraei M, Chabot-Doré AJ, Millecamps M, Stone LS, and Pineyro G (2012) Differential association of receptor-Gbg complexes with b-arrestin2 determines recycling bias and potential for tolerance of d opioid receptor agonists. J Neurosci 32:4827-4840.
5. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, and Piñeyro G (2003) Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100:11406-11411.
6. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, and Lin FT (1999) Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286: 2495-2498.
7. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, and Caron MG (2000) Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408:720-723.
8. Bohn LM, Gainetdinov RR, Sotnikova TD, Medvedev IO, Lefkowitz RJ, Dykstra LA, and Caron MG (2003) Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci 23:10265-10273.
9. Boström BM, Ramberg T, Davis BD, and Fridlund B (1997) Survey of post-operative patients' pain management. J Nurs Manag 5:341-349.
10. D'Amour FE and Smith DL (1941) A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74-79.
11. Dahan A (2007) Respiratory depression with opioids. J Pain Palliat Care Pharmacother 21:63-66.
12. DeWire SM, Ahn S, Lefkowitz RJ, and Shenoy SK (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483-510.
13. DeWire SM and Violin JD (2011) Biased ligands for better cardiovascular drugs: Dissecting G-protein-coupled receptor pharmacology. Circ Res 109:205-216.
14. Dixon WJ (1980) Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20:441-462.
15. Doll C, Konietzko J, Pöll F, Koch T, Höllt V, and Schulz S (2011) Agonist-selective patterns of m-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br J Pharmacol 164:298-307.
16. Eason MG, Jacinto MT, and Liggett SB (1994) Contribution of ligand structure to activation of alpha 2-adrenergic receptor subtype coupling to Gs. Mol Pharmacol 45:696-702.
17. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, Eckhardt AE, Cowan CL, Spurney RF, and Luttrell LM, et al. (2006) Distinct beta-arrestin-and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 281:10856-10864.
18. Gesty-Palmer D, Flannery P, Yuan L, Corsino L, Spurney R, Lefkowitz RJ and Luttrell LM (2009) A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 1:1ra1.
19. Gesty-Palmer D and Luttrell LM (2011) Refining efficacy: Exploiting functional selectivity for drug discovery. Adv Pharmacol 62:79-107.
20. Griffin MT, Figueroa KW, Liller S, and Ehlert FJ (2007) Estimation of agonist activity at G protein-coupled receptors: Analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15. J Pharmacol Exp Ther 321:1193-1207.
21. Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE, and Bohn LM (2007) An opioid agonist that does not induce mu-opioid receptor-arrestin interactions or receptor internalization. Mol Pharmacol 71:549-557.
22. Haberstock-Debic H, Kim KA, Yu YJ, and von Zastrow M (2005) Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons. J Neurosci 25:7847-7857.
23. Hamilton GR and Baskett TF (2000) In the arms of Morpheus the development of morphine for postoperative pain relief. Can J Anaesth 47:367-374.
24. Kenakin T (2011) Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336:296-302.
25. Kieffer BL (1999) Opioids: First lessons from knockout mice. Trends Pharmacol Sci 20:19-26.
26. Kim IM, Tilley DG, Chen J, Salazar NC, Whalen EJ, Violin JD, and Rockman HA (2008) Beta-blockers alprenolol and carvedilol stimulate beta-arrestin- mediated EGFR transactivation. Proc Natl Acad Sci USA 105:14555-14560.
27. LaBuda CJ and Little PJ (2005) Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat. J Neurosci Methods 144: 175-181.
28. Lazareno S and Birdsall NJ (1993) Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations. Br J Pharmacol 109:1110-1119.
29. Le Bars D, Gozariu M, and Cadden SW (2001) Animal models of nociception. Pharmacol Rev 53:597-652.
30. Lew MJ and Angus JA (1995) Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol Sci 16:328-337.
31. Li Y, Liu X, Liu C, Kang J, Yang J, Pei G, and Wu C (2009) Improvement of morphine-mediated analgesia by inhibition of beta-arrestin 2 expression in mice periaqueductal gray matter. Int J Mol Sci 10:954-963.
32. Ma L, Seager MA, Wittmann M, Jacobson M, Bickel D, Burno M, Jones K, Graufelds VK, Xu G, and Pearson M, et al. (2009) Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci USA 106:15950-15955.
33. Manchikanti L, Helm S, 2nd, Fellows B, Janata JW, Pampati V, Grider JS, and Boswell MV (2012) Opioid epidemic in the United States. Pain Physician 15(3, Suppl)ES9-ES38.
34. Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, Pardo L, Weis WI, Kobilka BK, and Granier S (2012) Crystal structure of the m-opioid receptor bound to a morphinan antagonist. Nature 485:321-326.
35. Marderstein EL and Delaney CP (2008) Management of postoperative ileus: Focus on alvimopan. Ther Clin Risk Manag 4:965-973.
36. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, and Dollé P, et al. (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioidreceptor gene. Nature 383:819-823.
37. Molinari P, Vezzi V, Sbraccia M, Grò C, Riitano D, Ambrosio C, Casella I, and Costa T (2010) Morphine-like opiates selectively antagonize receptor-arrestin interactions. J Biol Chem 285:12522-12535.
38. Ocaña M, Cendán CM, Cobos EJ, Entrena JM, and Baeyens JM (2004) Potassium channels and pain: Present realities and future opportunities. Eur J Pharmacol 500:203-219.
39. Raehal KM, Walker JK, and Bohn LM (2005) Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 314:1195-1201.
40. Raehal KM and Bohn LM (2011) The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology 60:58-65.
41. Rajagopal K, Whalen EJ, Violin JD, Stiber JA, Rosenberg PB, Premont RT, Coffman TM, Rockman HA, and Lefkowitz RJ (2006) Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA 103:16284-16289.
42. Rajagopal S, Ahn S, Rominger DH, Gowen-MacDonald W, Lam CM, Dewire SM, Violin JD, and Lefkowitz RJ (2011) Quantifying ligand bias at seventransmembrane receptors. Mol Pharmacol 80:367-377.
43. Rosethorne EM and Charlton SJ (2011) Agonist-biased signaling at the histamine H4 receptor: JNJ7777120 recruits b-arrestin without activating G proteins. Mol Pharmacol 79:749-757.
44. Sahbaie P, Modanlou S, Gharagozlou P, Clark JD, Lameh J, and Delorey TM (2006) Transcutaneous blood gas CO2 monitoring of induced ventilatory depression in mice. Anesth Analg 103:620-625.
45. Schneider JP and Kirsh KL (2010) Defining clinical issues around tolerance, hyperalgesia, and addiction: A quantitative and qualitative outcome study of longterm opioid dosing in a chronic pain practice. J Opioid Manag 6:385-395.
46. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, and Uhl GR (1997) Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 94:1544-1549.
47. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, and Journot L (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature 365:170-175.
48. Sternini C, Brecha NC, Minnis J, D'Agostino G, Balestra B, Fiori E, and Tonini M (2000) Role of agonist-dependent receptor internalization in the regulation of mu opioid receptors. Neuroscience 98:233-241.
49. Tohgo A, Choy EW, Gesty-Palmer D, Pierce KL, Laporte S, Oakley RH, Caron MG, Lefkowitz RJ, and Luttrell LM (2003) The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem 278:6258-6267.
50. Tyers MB (1980) A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol 69:503-512.
51. Urs NM, Daigle TL, and Caron MG (2011) A dopamine D1 receptor-dependent b-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice. Neuropsychopharmacology 36:551-558.
52. Violin JD and Lefkowitz RJ (2007) Beta-arrestin-biased ligands at seventransmembrane receptors. Trends Pharmacol Sci 28:416-422.
53. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, and Lark MW (2010) Selectively engaging b-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335:572-579.
54. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, and Lefkowitz RJ (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100:10782-10787.
55. Whistler JL and von Zastrow M (1998) Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci USA 95:9914-9919.
56. Yang CH, Huang HW, Chen KH, Chen YS, Sheen-Chen SM, and Lin CR (2011) Antinociceptive potentiation and attenuation of tolerance by intrathecal b-arrestin 2 small interfering RNA in rats. Br J Anaesth 107:774-781.